Categories

We are honored by the ongoing recognition of Forbes Magazine for the outstanding business growth that our employees have achieved as we continue to drive superior value for our customers and our shareholders. This year Myriad moved up 33 spots in the Forbes ranking to number 16. The ranking reflects Myriad’s outstanding business performance. In…

Continue Reading

At Myriad, we regularly reach out to our customers in the medical and scientific communities as part of our ongoing process to understand their needs and then work with them to identify solutions to help them achieve their goals. Six or seven years ago, I embarked on one such fact-finding mission to better understand the…

Continue Reading

October is Breast Cancer Awareness Month and once again Myriad Genetics, Inc. is proud to be joining efforts with the American Cancer Society to support Making Strides against Breast Cancer. Mark your calendar and join us at this year’s Making Strides Against Breast Cancer Walk scheduled for Saturday October 12, 2013 from 8:00am to 1:00pm…

Continue Reading

Break Out the Teal! September is Ovarian Cancer Awareness Month! According to the National Cancer Institute’s website 22,240 women will be diagnosed with ovarian cancer in 2013. Approximately 11 – 15% of these diagnosed ovarian cancer cases are caused by mutations in the BRCA1 or BRCA2 genes. That means that 1 in 7 women who…

Continue Reading

Data recently presented by Myriad Genetics’ prostate cancer prognostic test Prolaris is getting healthcare professionals and patients interested in learning more about how the multi-gene prognostic test can be used to gauge prostate cancer aggressiveness. Myriad Genetics presented data at the American Society of Clinical Oncology’s annual meeting from five studies involving Prolaris, all suggesting…

Continue Reading

Not many of us can look at a genetic code and be inspired to create artwork from it. For most people a DNA sequence looks like a jumble of letters, wavelengths and bright colors. Max Nanis, however, is not “most people.” Max has married his artistic and scientific backgrounds into a project that he is…

Continue Reading

We’re in the business of saving lives.  That’s what really matters to me, and to the very bright people who work with me at Myriad.  We offer testing for patients who, based on their family history, are concerned they are at increased genetic risk for cancer.  If a woman learns from our test that she…

Continue Reading

Saturday, March 9, 2013 was a chilly morning on the coast of southern California but OH WHAT A DAY! Twenty eight people and one boxer joined Team Myriad for the 2013 Undy 5000 at Mission Bay Park in San Diego to show support and raise awareness about colorectal cancer and hereditary colon cancer syndromes. Team…

Continue Reading

SALT LAKE CITY, March 5, 2013 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a study published in the Journal of Clinical Oncology demonstrated that its Prolaris test, which analyzes the expression level of 46 cell cycle progression genes, accurately predicted the elevated risk for prostate cancer recurrence in 413 men who had undergone a radical…

Continue Reading

February 6, 2013 RE: COLARIS® and COLARIS AP® MYH Enhancements Myriad Genetic Laboratories, Inc. is pleased to announce enhancements to our COLARIS® and COLARIS AP® testing for Lynch syndrome and Polyposis syndromes. These important enhancements demonstrate our ongoing commitment to providing the most accurate and complete testing services possible for common hereditary cancer syndromes. COLARIS…

Continue Reading

Adam A. Ofer, MD, is a board-certified Ob/Gyn and the Director of Gynecology at the Norwalk Hospital in Connecticut.  His focus is in urogynecology and minimally-invasive surgery, including da Vinci surgery (a minimally invasive alternative to both open surgery and laparoscopy).    We are very lucky to have Dr. Ofer as one of our healthcare…

Continue Reading

There are limited recommendations on this topic.1 The following summarizes the literature, however, a clinician’s judgment will also be based on the patient’s age, co-morbidities and individual circumstances. Management after risk-reducing mastectomy Prophylactic mastectomy reduces the risk of breast cancer in BRCA carriers by about 90%,2

Continue Reading

The holidays are known as a time for giving and Myriad proudly helped bring that giving spirit to the Cancer Wellness House’s annual holiday party.  The Cancer Wellness House has been serving Salt Lake City and its surrounding areas since 1997 with the goal of supporting and uniting people and families dealing with cancer through…

Continue Reading

SALT LAKE CITY, Dec. 17, 2012 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the 2013 J.P. Morgan Annual Healthcare Conference, at 9:30 a.m. Pacific Time on Monday, January 7, 2013. The conference is being held at the Westin St. Francis in San…

Continue Reading

Myriad RBM to Perform Protein Biomarker Discovery on Over 8,000 Serum Samples From Patients With Pre-Diabetes or Type 2 Diabetes SALT LAKE CITY, Dec. 10, 2012 (GLOBE NEWSWIRE) — Myriad Genetics (Nasdaq:MYGN) announced today that Myriad RBM, a wholly owned subsidiary of Myriad Genetics, has entered into a research collaboration with Sanofi, a global and diversified healthcare leader, andPopulation Health…

Continue Reading

This past week Myriad Genetic Laboratories had the opportunity to present 2 posters at the Society for Urologic Oncologists that was held in Bethesda, MD.  The first poster, DEVELOPMENT AND VALIDATION OF A MULTIVARIATE MODEL COMBINING CELL CYCLE PROGRESSION SCORE WITH CAPRA TO PREDICT PROSTATE CANCER MORTALITY IN A CONSERVATIVELY MANAGED COHORT was presented by…

Continue Reading

SALT LAKE CITY, Nov. 28, 2012 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled “CCP Score Significantly Predicts PSA Failure After EBRT,” was presented on Wednesday, November 28th, 2012 at the Annual Meeting of the Society of Urological Oncology in Bethesda, Maryland. The study demonstrates that the Prolaris® test, which measures cell cycle progression (CCP) genes, significantly predicts PSA…

Continue Reading

In the last weeks, Myriad Genetics has been conducting alumni speaker trainings for its front-line healthcare professional and mid-level providers. These providers have previously worked with Myriad to speak with their peers in a variety of settings, from presentations to a large number of providers at sponsored events,  at medical society meetings and meeting one…

Continue Reading

The National Ovarian Cancer Coalition (NOCC)’s 2012 Conference in Las Vegas, Nevada was held November 8th through 10th. Survivors, caregivers, healthcare professionals, and family members gathered to embrace the great strides and impact being made by the NOCC in their mission to raise awareness about the signs and symptoms of ovarian cancer. Myriad provided a…

Continue Reading

Know Your Skin Hereditary melanoma is just one risk factor for this rare but deadly form of skin cancer.  Knowing your skin and checking it monthly is the first step in preventing melanoma.   Make the 1st day of the month an easy day to remember to check your skin for the signs of skin cancer. …

Continue Reading

Today’s Myridian Monday spotlight is on John Ryan, the Senior Director of Operations and an employee of Myriad for over 12 years. I have worked at Myriad for over 12 years in a variety of roles.  In my current role, I am involved with the operational production of our diagnostic tests.  Currently I help manage the…

Continue Reading

This fall Myriad participated in eleven National Ovarian Cancer Coalition Walks to Break the Silence on Ovarian Cancer with just one more walk to go in San Antonio, Texas this November.  Between team building, fundraising, information giving, walking and just plain having fun, Myriad was able to raise awareness about both hereditary breast and ovarian…

Continue Reading

A group of Myriad employees attended the Annual Huntsman Cancer Foundation Gala and Survivorship Celebration last Thursday evening at the Grand America Hotel in downtown Salt Lake City. Myriad has been a supporter of the event for several years, and both Huntsman and Myriad share a similar vision for future advancements in cancer technologies and…

Continue Reading

Myriad Genetics is being featured in the November edition of Forbes Magazine! Read the article online HERE and grab a copy when it hits newsstands on November 5th  — Natalie VavrasekInteractive Associate Product Manager

Continue Reading

On September 28th, 2012 Myriad partnered with Living Beyond Breast Cancer (LBBC) to educate breast cancer survivors at the Annual LBBC Conference about Hereditary Breast and Ovarian Cancer syndrome. In a very casual setting atop the 33rd floor of the Loews Hotel in downtown Philadelphia, Cynthia Kimball – patient advocate and breast cancer survivor and Jill…

Continue Reading

We would like to take a few Mondays each month to introduce you to some of our shining star employees here at Myriad Genetics. These employees exemplify what it means to be a Myridian. Their efforts at the office and in the community are what Myriad stands for! Our first spotlight is on Colleen Walch, a Patient…

Continue Reading

This BRCA2 positive patient has had a mastectomy and prostatectomy. Yes, you read that correctly. Meet Robert, a male HBOC carrier and breast cancer survivor!  I am 53 years old and yes, a breast cancer survivor!. I raised two sons as a single dad and have two grandchildren, with a third on the way. One…

Continue Reading

Leslie had everything planned for her upcoming Thanksgiving feast. Her Christmas shopping lists were in order, and she was ready to host the rehearsal party for her son’s December 28th wedding. What she wasn’t ready for, was the unexpected arrival of cancer. In the 1970s I lost both of my parents to cancer. They were…

Continue Reading

Today was an inspirational day here at Myriad.  We had two amazing speakers on hand to discuss their organizations, David Barley, CEO of National Ovarian Cancer Coalition, (NOCC) as well as a representative from Bright Pink.  It was very powerful to hear about all the amazing advocacy work each organization is doing.  (Pictured Above: David Barley,…

Continue Reading

September 26, 2012 is National Previvor Day. At Myriad, we believe knowledge is power, and Previvors embody this sentiment. A Previvor refers to an individual who carries a strong predisposition to cancer but has not developed cancer. These individuals proactively sought out knowledge to determine if they inherited a gene mutation by having genetic testing…

Continue Reading

More than 20,000 women are diagnosed with ovarian cancer each year, and approximately 15,000 women die from the disease each year. Since there is no early detection test, most cases are diagnosed in later stages when prognosis is poor. When ovarian cancer is found early at a localized stage, prognosis is good for the majority…

Continue Reading

Hi my name is Rebecca and I want to welcome you to the Myriad Genetics Blog! We wanted to share with you all some interesting things we are doing here and will also include some things our friends are talking about. We expect to cover many different topics including research work being done at Myriad, patient…

Continue Reading